ntithrombin therapy with heparin is the evidencebased standard treatment for patients with acute coronary syndrome without ST elevation (NSTE ACS). 1,2 Low-molecular-weight heparin (LMWH) has several advantages over unfractionated heparin (UFH), including a more predictable anticoagulant effect, better bioavailability, a longer half-life, and simpler application without the need for laboratory monitoring. 3 As the recent data from the registries shows, most patients with NSTE ACS are treated with UFH, and this is also true for most of the highrisk patients undergoing an early (≤48 h) invasive strategy. 4,5 This could be the consequence of routine, in addition to being related to the capability of stopping antithrombin therapy at the time of percutaneous coronary intervention and also the opportunity to manage this therapy through intervention according to timely measured activated clotting time. Additionally, treatment with (recommended dose of) UFH can be started safely without knowledge of renal function. In contrast to previous investigations, a rapid rebound increase in coagulation activity occurs soon after discontinuation of UFH, as well as with LMWH. 6,7 Dual antiplatelet therapy (ie, aspirin plus clopidogrel) reduces this reactivation. 8 In our practice, patients are routinely treated with UFH before admission to a cardiocenter (emergency medical service, community hospital). Changing antithrombin therapy during the course of treatment is associated with an increased risk of bleeding. 9 It is clear that UFH is, and will be, a very important part of the antithrombin therapy for NSTE ACS patients. As the recent Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology recommend, UFH is to be preferred in high-risk NSTE-ACS patients with a planned invasive strategy. 10 The most vulnerable part of its application is correct dosing.For these reasons, we investigated the quality of UFH treatment in daily clinical practice in a university teaching hospital, to determine what proportion of high-risk NSTE ACS patients with early invasive management treated with continual infusion of UFH reached the target optimal values of activated partial thromboplastin time (aPTT). The aim of this analysis was to define the risk factors associated with problematic dose titration of UFH in high-risk NSTE ACS patients.
Methods
SubjectsWe analyzed a group of 267 consecutive patients admitted to the Coronary Care Unit with high-risk NSTE ACS and adequately treated with the recommended dose of UFH. The data from 136 patients were collected retrospectively and from 131 patients prospectively. Patients were managed with an early (≤48 h) invasive strategy. All study participants were on dual antiplatelet therapy consisting of aspirin (100 mg daily) and clopidogrel (initial loading dose 300 mg and maintenance dose 75 mg daily). In this institution, the Circ J 2008; 72: 1674 -1679 (Received January 21, 2008 revised manuscript received May 22, 2008; accepted June 9, 2008; released online September 1, 200...